Loading

Commentary Open Access

Neuropeptide FF receptor activation as a novel modulator of N-type calcium channel-mediated analgesia: Expanding the therapeutic potential of ziconotide

  • 1Institute of Basic Medicine, North Sichuan Medical College, 1 North Yida Road, Nanchong 637000, PR China
+ Affiliations - Affiliations

Corresponding Author

Zhenglan Han, hanzhenglan@nsmc.edu.cn 

Received Date: April 16, 2026

Accepted Date: June 06, 2026

Abstract

The management of severe, refractory chronic pain remains a major unmet clinical need, complicated by opioid limitations and the narrow therapeutic window of intrathecal ziconotide, a selective N-type voltage-gated calcium channel (CaV2.2) blocker. A recent study by Jin et al. provides the first in vivo evidence that spinal neuropeptide FF (NPFF) receptor signaling functionally cross-talks with CaV2.2 to enhance ziconotide-evoked antinociception without inducing tolerance. This commentary integrates advances in GPCR-ion channel crosstalk, receptor subtype pharmacology, and translational pain medicine. We discuss that NPFF-based combinatorial strategies can enhance ziconotide’s analgesic efficacy, potentially allowing a reduction in ziconotide dosage to mitigate its neurological side effects and thereby inform the development of novel combinatorial analgesic strategies for clinically accessible intrathecal delivery. We also highlight unresolved questions regarding NPFF1/NPFF2 subtype contributions, cell-type-specific signaling, and translatability to human pathological pain. The NPFF-CaV2.2 axis represents a promising target to revolutionize non-opioid pain pharmacotherapy.

Keywords

Neuropeptide FF, Ziconotide, CaV2.2 channel, Pain, GPCR-ion channel crosstalk

Author Information X